ArticleHernia : the journal of hernias and abdominal wall surgery2026
Measuring symptoms in parastomal hernia: a prospective evaluation using MYMOP2.
Article in Hernia : the journal of hernias and abdominal wall surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParastomal hernia (PSH) is a common complication following stoma formation, associated with pain, and impaired quality of life (QoL). Despite this, no validated disease-specific patient-reported outcome measure (PROM) exists for PSH. Non-operative interventions on symptom burden have not been well quantified. The Measure Yourself Medical Outcome Profile (MYMOP2), a patient-generated tool, may capture PSH-specific symptoms and their change over time.
objectiveTo evaluate changes in patient-reported symptom burden, using MYMOP2, following surgical or conservative management in a dedicated specialist PSH clinic.
methodsA single-centre prospective cohort study included consecutive patients attending a monthly multidisciplinary PSH-only clinic between May 2022 and October 2025. From February 2023, all new patients completed MYMOP2 at baseline and at follow-up (≥ 2 months post-intervention). Demographic and clinical data were obtained from clinical records. The primary outcome was change in MYMOP2 Profile score. Secondary outcomes were changes in domain-specific scores (Symptom 1, Symptom 2, Overall Symptom Score, Activity and Wellbeing) and comparisons between conservative and surgical management.
resultsOf 137 patients, 36 completed baseline and follow-up MYMOP2 data (14 conservative, 22 surgical). Baseline MYMOP2 Profile scores were similar (median 16 for both groups). Surgical repair produced significant improvements in MYMOP2 Profile (16 to 5.5, p < 0.0001), Overall Symptom (8.5 to 2, p < 0.0001), Wellbeing (4 to 1.5, p = 0.0015) and Activity scores (4.5 to 2, p < 0.001). Conservative management also resulted in improvements in Profile (16 to 7, p < 0.001), Overall Symptom Score (8 to 3, p = 0.002) and Activity (5 to 1.5, p = 0.005).
conclusionA dedicated multidisciplinary PSH clinic achieves meaningful reductions in patient-reported symptom burden following conservative and surgical management. Although surgery yields greater improvement, non-operative interventions also provide benefit. MYMOP2 is a pragmatic outcome measure for PSH and merits further validation in larger cohorts.
Indexed as
Identifiers
41995772What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.